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Abstract—Gender-affirming or cross-sex hormone therapy is integral to the management of transgender individuals yet our 
appreciation of the effects of such hormones on cardiovascular health is limited. Insights into vascular pathophysiology 
and outcomes in transgender people receiving sex steroids could be fundamental in providing better care for this 
population through the management of cardiovascular risk and more broadly advance our understanding of the role of 
sex and gender in vascular health and disease. In addition, there is a need to understand how gender-affirming hormone 
therapy impacts cardiovascular disease risk and events as transgender individuals age. This review explores the available 
evidence on the associations between gender-affirming hormones and cardiovascular events such as coronary artery 
disease, stroke, hypertension, thrombosis, lipid abnormalities, and diabetes mellitus. Current research about vascular 
outcomes in adults receiving hormonal therapy is limited by the absence of large cohort studies, lack of appropriate 
control populations, and inadequate data acquisition from gender identity services. Existing epidemiological data 
suggest that the use of estrogens in transgender females confers an increased risk of myocardial infarction and ischemic 
stroke. Conversely, transgender males receiving testosterone lack any consistent or convincing evidence of increased 
risk of cardiovascular or cerebrovascular disease. Further studies are required to confirm whether such risk exists and 
the mechanisms by which they occur.
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Transgender people experience gender dysphoria due to in-congruence between their gender identity and the sex they 
were assigned at birth (Table 1).1 Due to lack of accurate census 
data, barriers to healthcare such as social stigma and variable 
engagement with gender-affirming healthcare, the size of the 
transgender population is uncertain, however, it is estimated 
to represent ≈0.5% of the US population.1–5 An expansion in 
population prevalence and the utilization of transgender health 
services has been observed in recent years.6–8
Gender-affirming hormone therapy (GHT) aims to align 
the characteristics of an individual with their gender identity. 
The mainstay of this lifelong treatment in transgender males 
(TGM) is testosterone, typically delivered as intramuscular 
testosterone undecanoate or ester formulation. Transgender 
females (TGF) receive oral or transdermal estrogen prepara-
tions (eg, estradiol valerate or hemihydrate) often in conjunc-
tion with either a gonadotropin-releasing hormone analog (eg, 
Goserelin) or an anti-androgen (eg, cyproterone acetate).9,10
A deeper understanding of the alterations in vascular pa-
thology and outcomes in transgender people receiving GHT 
could be fundamental in informing the management of car-
diovascular risk. This review outlines the current evidence 
relating to the effects of GHT, and in particular exogenous 
testosterone and estrogen, on vascular health outcomes in 
transgender adults.
Transgender Health
Ischemic Heart Disease
The first observational study relating to GHT and cardiovas-
cular disease (CVD) was published in 1989 (Table 2). This 
did not demonstrate any difference in the crude incidence of 
myocardial infarction (MI) or mortality relating to MI over 
a 4-year follow-up period when comparing 303 TGF to cis-
gender males (CGM). No cases of MI were noted within the 
TGM group.11
In 1997, van Kesteren et al12 undertook a retrospective ob-
servational study in 816 TGFs and 293 TGMs receiving GHT 
with a respective follow-up of 7734 and 2418 patient-years. 
This study demonstrated a decreased standardized incidence 
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ratio (SIR) of MI in TGFs (SIR, 0.5 [95% CI, 0.24–0.91]) 
compared with CGMs. There was no difference in MI stan-
dardized mortality ratio (SMR, 0.71 [95% CI, 0.26–1.55]). 
SIR was no different in TGMs compared with cisgender 
females (CGFs).
In 966 TGFs and 365 TGMs with a median follow-up of 
18.5 years, mortality was 51% higher compared with the ge-
neral population.13 This was attributed to increased suicide, 
HIV infection, CVD, and substance abuse. TGFs had a SMR 
of 1.64 (95% CI, 1.43–1.87) relating to ischemic heart disease. 
The adjusted hazard ratio (HR) for cardiovascular mortality 
was 3.12 (95% CI, 1.28–7.63) in those using ethinylestradiol 
compared to former or never-users. TGM demonstrated a 
nonsignificant SMR of 1.19 (95% CI, 0.39–2.74) for ischemic 
heart disease mortality.
A population-based matched cohort study of 324 trans-
gender people who had undergone gender reassignment 
surgery with mean follow-up of 11 years demonstrated an 
increased risk of cardiovascular death (HR, 2.5; 95% CI, 
1.2–5.3) compared with cisgender people.14 In a cohort 
study of 100 transgender people retrospectively followed-
up for 10 years, 2 cases of MI were identified in TGFs and 
no cases in TGM.15 A cross-sectional study in 138 TGM 
and 214 TGFs receiving GHT over an average of 7.7 years 
(range 4–13 years) demonstrated significantly increased 
prevalence of MI in TGFs (18.7 per 1000) compared with 
CGFs but not CGMs.16
Studies using data from the Behavioral Risk Factor 
Surveillance System showed that transgender individuals are 
at greater risk of MI than cisgender individuals.17–19 Meyer et 
al17 reported a higher odds ratio (OR) of MI in transgender 
(OR, 1.82 [95% CI, 1.22–2.72]) compared with cisgender 
people, with no increased risk of angina or coronary heart 
disease (OR, 1.37 [95% CI, 0.83–2.25]). Nokoff et al18 dem-
onstrated an increased risk of MI (OR, 2.9 [95% CI, 1.6–
5.3]) in TGFs compared with CGFs, but not CGMs (OR, 1.09 
[95% CI, 0.59–2.03]). There was no increased risk comparing 
TGMs to CGMs or CGFs. The risk of angina or coronary 
heart disease was not increased in either TGFs or TGMs. 
Conversely, Alzahrani et al19 demonstrated that TGM but not 
TGF had an associated higher risk of MI compared with their 
natal sex comparators after adjusting for traditional CVD 
risk factors. Importantly these studies are cross-sectional, do 
not confirm the use of GHT and rely on the self-reporting of 
health issues such as MI and are, therefore, at risk of signif-
icant bias.
In a retrospective analysis of electronic medical records 
between 2006 and 2014, 2842 TGFs and 2118 TGMs re-
ceiving GHT were followed up for 4.0 and 3.6 years, respec-
tively. A higher rate of MI in TGFs was observed compared 
with CGFs (HR, 1.8 [95% CI, 1.1–2.9]).20 However, this was 
not increased when compared with CGMs (HR, 0.9 [95% 
CI, 0.6–1.5]). Again, no differences were observed between 
TGMs, CGMs, or CGFs.
Overall, evidence derived from age-adjusted popula-
tion comparisons and age-matched cohort studies suggest 
that TGFs have a higher risk of CVD and ischemic events 
than CGFs, however, in only one study was this higher than 
CGMs.13 Importantly, most studies use TGF populations under 
the age of 50 years, and little is known of the impact of GHT 
on vascular health in the longer term. As discussed in recent 
meta-analysis, there is a paucity of data about important pa-
tient outcomes, such as MI, and the ability to draw conclusion 
from studies where control groups and age-matched cohorts 
are not clearly defined impedes any meaningful assessment.21 
No consensus exists on whether a transgender person’s car-
diovascular risk should be compared with their natal sex or 
gender.
Cerebrovascular Disease
In an observational study of 303 TGFs followed up for a me-
dian of 4.4 years, there were no differences in the crude in-
cidence of transient ischemic attack compared with CGMs.11 
Similar results were observed by van Kesteren et al,12 who 
did not demonstrate any significant difference in SIR for cere-
brovascular disease in TGFs. In a study of 966 TGFs and 375 
TGMs with a median follow-up of 18.5 years, there was no 
difference in mortality associated with stroke in TGFs and no 
cases at all in TGMs.13
More recently, Wierckx et al16 undertook a case-control 
study in 214 TGFs and 138 TGMs with an average of 7.7 
years GHT and mean age of 43 years. TGFs demonstrated a 
higher prevalence of transient ischemic attack and cerebrovas-
cular disease (23.4 per 1000), which, although no different 
from age-matched CGFs (14.9 per 1000), was significantly 
higher than age-matched CGMs (9.4 per 1000). No cases were 
observed in CGMs.
Survey data demonstrated no difference in cerebrovas-
cular disease risk in transgender compared with cisgender 
populations.17 When stratified between TGFs and TGMs there 
was no increased risk in comparison to CGMs or CGF.18 The 
use of GHT was uncertain in these populations.
Getahun et al20 undertook an electronic medical record-
based cohort study in 2842 TGFs and 2118 TGMs. TGFs had 
higher rates of ischemic stroke compared with corresponding 
rates in CGM and CGF. Ischemic stroke rates were highest 
in a sub-analysis of 853 TGFs who initiated GHT during the 
study period. These rates did not differ compared with cis-
gender populations during the first 6 years of follow-up but 
thereafter increased substantially compared with both CGMs 
(HR, 9.9 [95% CI, 3.0–33.1]) and CGFs (HR, 4.1 [95% CI, 
1.5–11.4]).
Although uncertainty remains, TGFs appear to be at a 
higher risk of developing ischemic stroke compared with cis-
gender populations. This risk is most evident in longer-term 
estrogen use. Conversely, TGMs do not have increased cere-
brovascular disease risk.
Hypertension
Numerous studies have suggested an increased incidence 
of hypertension in transgender populations. Asscheman 
et al11 observed an increase in the crude incidence of hy-
pertension in 303 TGFs. However, no increase was dem-
onstrated in TGMs. The SIR for hypertension (defined as 
>160/95 mm Hg) was not significantly higher in TGFs or 
TGMs compared with CGMs and CGFs, respectively. In a 
cohort study comparing 63 untreated TGMs to 48 TGMs 
undergoing GHT, the resting systolic and diastolic brachial 
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blood pressures (BPs) in the treated group were significantly 
higher.22 After 2 years of GHT in 79 TGFs and 43 TGMs, the 
mean of 3 consecutive systolic BPs increased significantly 
by 17.8 mm Hg and 13.4 mm Hg, respectively.23 The TGF 
group also demonstrated a 3.17 mm Hg increase in diastolic 
BP, which was not noted in the TGM group.23 Lastly, self-
reported hypertension in 369 TGFs and 239 TGMs was no 
higher when compared with cisgender populations.18
Furthermore, prospective studies demonstrated alteration 
in BP following GHT initiation. In a study of 20 TGFs com-
mencing GHT an increase in both mean systolic (7 mm Hg) 
and diastolic (5.7 mm Hg) BP (measured every 5 minutes for 
2 hours using an automatic device) was noted at one year.24 No 
significant changes in BP were noted in 17 TGMs in this time-
frame. Oral estradiol valerate has been shown to reduce sys-
tolic BP by 6.3 mm Hg after 1 year in 40 TGFs. This was not 
observed in a transdermal estrogen cohort (n=13) or in TGMs 
receiving testosterone undecanoate.25 TGMs treated with in-
tramuscular testosterone have demonstrated a 3.2 mm Hg in-
crease in systolic but not diastolic BP.26 In 2019, van Velzen 
et al27 reported a prospective observational study of 242 TGFs 
and 188 TGMs, where BP was measured via an automated de-
vice 12 months after commencing GHT. In TGMs, no change 
was observed in systolic BP. However, diastolic BP signifi-
cantly increases by 3 mm Hg in the pooled analysis. In TGFs, 
in whom 59.5% used oral estrogen valerate and 40.5% were 
prescribed transdermal estrogen patches, systolic and diastolic 
BP decreased by 3 and 2 mm Hg, respectively.
Results from these studies are inconsistent, and alterations 
in BP may be dependent on factors such as GHT duration and 
age. GHT appears to elevate BP in both TGMs and TGFs in 
most studies. However, this may only be apparent with longer-
term use.
Venous Thromboembolism
GHT may also promote CVD by altering the thrombotic phe-
notype. Early observational studies demonstrated a 20 to 45 
fold increase in the rates of venous thromboembolism (VTE) 
in GHT-exposed TGF.11,12 In a more recent retrospective anal-
ysis, VTE developed in 1.2% of TGF receiving oral therapy 
for 2 years and was more common in those exposed to conju-
gated equine estrogen (4%) compared with estrogen valerate 
(0.6%) or ethinylestradiol (0.7%).28 Subsequently, a case-
control study of 214 TGFs with a mean estrogen duration of 
7.7 years VTE occurred in 5.1%.16 The higher risk of VTE 
observed by Getahun increased with time, with 2- and 8- year 
risk differences of 4.1 (95% CI, 1.6–6.7) and 16.7 (95% CI, 
6.4–27.5) per 1000 persons relative to CGM.20 Although the 
majority of studies demonstrate an increased risk in TGFs, 
this finding is not uniform.29,30 To our knowledge, no study has 
demonstrated an increased risk of VTE in TGMs.
Cardiometabolic Risk
GHT may also alter cardiometabolic parameters through 
which it may modify CVD risk. In a recent systematic review 
and meta-analysis 29 studies, including 4731 transgender indi-
viduals (68% TGFs) with follow-up ranging from 3 months 
to 41 years, were assessed.21 Testosterone therapy in TGMs, 
at greater than 2 years follow up was associated with an ele-
vation in triglycerides (21.4 mg/dL; 95% CI, 0.14–42.6) and 
Figure 1. Vascular effects of sex steroids via estrogen and androgen receptors expressed in endothelial, vascular smooth muscle, and myocardial cells.
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LDL (low-density lipoprotein; 17.8 mg/dL; 95% CI, 3.5–32.1) 
with reductions in HDL (high-density lipoprotein; −8.5 mg/
dL; 95% CI, −13 to −3.9) with no significant change in total 
serum cholesterol. Conversely, no significant differences were 
apparent in LDL, HDL, or total cholesterol in TGFs, but an 
increase in triglycerides was observed (31.9 mg/dL; 95% CI, 
3.9–59.9). Although this assessment is limited by low-quality 
evidence, it raises questions as to why lipids do not reflect their 
adopted and more favorable gender profile in TGF and why 
this shift in TGM does not confer an increased risk of CVD.
It has also been suggested that an increased risk of type 2 
diabetes mellitus may exist in this population. In an observa-
tional study of 966 TGFs receiving cyproterone acetate and 
either oral or transdermal estrogen, there was no significant 
difference in diabetes mellitus-related SMR compared with 
the cisgender population (SMR 0.85; 95% CI, 0.41–1.32), 
while no cases were identified in 365 TGMs.13 In a cross-sec-
tional study completed in 214 TGFs and 138 TGMs, there 
were higher rates of diabetes mellitus in TGFs compared with 
CGFs or CGMs (42 per 1000 cases).16 TGMs demonstrated a 
higher incidence (36.2 per 1000 cases) compared with CGFs 
but not CGMs. Increases in homeostatic model assessment 
for insulin resistance index in TGFs has been demonstrated 
after 2 years of transdermal estrogen, but not after 1 year or in 
TGM.23,31 Fasting blood glucose in TGF is higher with trans-
dermal estrogen but not oral ethinylestradiol.23,24 Studies using 
the self-reporting Behavioral Risk Factor Surveillance system 
with no GHT confirmation did not demonstrate a higher risk of 
diabetes mellitus.17,18 Consequently, the relationship between 
GHT and altered glucose metabolism remains uncertain.
Surrogate Markers of Cardiovascular Risk in 
Transgender People
Few studies have assessed the effects of GHT on surrogate 
markers of cardiovascular risk in transgender people. TGFs 
prescribed either ethinylestradiol or conjugated estrogen 
for an average 61 months demonstrated improvements in 
Figure 2. Putative model for increased vascular 
risk in transgender women.
Table 1. Terms Used in Transgender Medicine
Terms Definition
Sex The classification of a person as male or female, 
typically occurring at birth, based on biological 
characteristics such as genitalia, reproductive 
organs, chromosomes, and hormones
Gender identity A person’s intrinsic sense of being male, female or 
an alternative gender
Cisgender People whose gender identity aligns with their 
natal sex
Gender dysphoria Distress caused by a discrepancy between a 
person’s gender identity and assigned sex
Transgender An umbrella term for people whose gender identity 
differs from their natal sex
Transgender male A person whose sex was assigned female who 
identifies as male
Transgender female A person whose sex was assigned male who 
identifies as female
Gender-affirming 
hormone therapy
Hormonal therapy aiming to align the physical 
characteristics of an individual with their gender 
identity
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Table 2. Ischemic Heart Disease in Transgender Populations
Author, y Population Design GHT Exposure Study Duration Outcome Measure
Asscheman et al11 303 TGF, 122 TGM Retrospective longitudinal 
study (no control group)
TGF, Ethinylestradiol 100 µg/d 
and CPA 100 mg/d orally; TGM, 
Testosterone esters 250 mg/2 wk 
IM or testosterone undecanoate, 
120–160 mg/d orally
Median follow-
up: TGF, 4.4 y; 
TGM, 3.6 y
Myocardial infarction morbidity, 
TGF vs CGM, 2 (95% CI 0.25–
7.2) vs 0.62 expected cases 
in ages 15–64; and TGM, no 
cases; and myocardial infarction 
mortality, TGF vs CGM: 1 (95% 
CI, 0.024–5.5) vs 0.62 expected 
cases in ages 15–64
van Kesteren et al12 816 TGF, 293 TGM Retrospective longitudinal 
study (no control group)
TGF, ethinylestradiol 100 µg/d 
and CPA 100 mg/d orally or 
transdermal estradiol; TGM, 
testosterone esters 250 mg/ 2 wk 
IM or testosterone undecanoate 
160 mg/d orally
TGF, 7734 patient 
years; TGM, 2418 
patient years
Myocardial infarction, TGF 
vs CGM: SIR 0.5 (95% CI, 
0.24–0.91),* SMR 0.71 (95% CI, 
0.26–1.55); TGM vs CGF, SIR 
0.34 (95% CI, 0.01–1.92); and 
SIR/SMR calculated from the 
general Dutch population (age- 
and gender-adjusted)
Asscheman et al13 966 TGF, 365 TGM Retrospective longitudinal 
cohort-study
TGF, ethinylestradiol, conjugated 
estrogens, estrogen valerate 
orally, or estrogen injections, 
or transdermal estrogens±CPA 
100 mg/d and spironolactone 
100–200 mg/d orally; TGM, 
testosterone esters 250 
mg/2–3 wk IM or testosterone 
undecanoate 160–240 
mg/d orally or transdermal 
testosterone 50 mg/d
Median follow-
up: 18.5 y
IHD disease mortality, TGF: SMR 
1.64 (95% CI, 1.43–1.87),* 
TGM: SMR 1.19 (95% CI, 
0.39–2.74); Cardiovascular 
mortality (ethinylestradiol use), 
TGF: Crude HR 2.82 (95% CI, 
1.19–6.65),* adjusted HR 3.12 
(95% CI, 1.28–7.63)* vs never 
and former users
Dhejne et al14 191 TGF, 133 TGM Population-based 
matched cohort study
Gender reassignment surgery, no 
GHT defined
Mean follow-up: 
11 y
Cardiovascular mortality, TG vs 
CG: Adjusted HR 2.5 (95% CI, 
1.2–5.3)*
Wierckx et al15 50 TGF, 50 TGM Retrospective, cohort 
study
TGF: 1 y of CPA (50–100 mg) 
followed by estrogen either 
transdermal estradiol gel 1.5 mg/24 
h, transdermal estradiol patch 50 
µg/d, or oral estrogens (estradiol 
valerate, estriol, ethinylestradiol); 
TGM: Testosterone esters 250 
mg/2–3 wk IM or testosterone 
1g/12 wk IM or testosterone 
undecanoate orally or transdermal 
testosterone 50 mg/d
Mean follow-up: 
10 y
Myocardial infarction, TGF: 2 
cases; TGM: No cases
Wierckx et al16 214 TGF, 138 TGM Retrospective, cross-
sectional
TGF: Transdermal estradiol 
gel 1.5 mg/d or transdermal 
estradiol patch 50 µg/d or oral 
estrogens (valerate 2 mg/d, 
estriol 2 mg/d, ethinylestradiol 
30–50 µg/d); TGM: Testosterone 
decanoate 100 mg, testosterone 
isocaproate 60 mg, testosterone 
phenylpropionate 60 mg, and 
testosterone propionate 30 mg/
mL)/2–3 wk IM, testosterone 
undecanoate 1g/12 wk IM, 
transdermal testosterone 50 
mg/d, or oral testosterone 
undecanoate
Mean duration of 
treatment: 7.7 y 
(range: 4–13 y)
Myocardial infarction 
prevalence, TGF: 18.7 per 1000 
cases vs CGF (P=0.001)*/CGM 
(P=NS), TGM: No cases
Meyer et al17 691 TG Retrospective, cross-
sectional, self-reported
Self-defined as transgender, no 
GHT defined
Lifetime history Myocardial infarction, TG vs CG: 
OR 1.82 (95% CI, 1.22–2.72)*; 
angina/coronary heart disease, 
TG vs CG: 1.37 (95% CI, 
0.83–2.25)
(Continued )
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Nokoff et al18 369 TGF, 239 TGM, 
and 156 GNC
Retrospective, cross-
sectional, self reported
Self defined as transgender, no 
GHT defined
Lifetime history Myocardial infraction: TGF vs 
CGF: OR 2.9 (95% CI, 1.6–5.3)*/
CGM OR 1.09 (95% CI, 0.59–
2.03), TGM vs CGM OR 0.48 
(95% CI, 0.16–1.51)/CGF OR 
1.28 (95% CI, 0.41–3.98); and 
angina/coronary heart disease, 
TGF vs CGF OR 1.95 (95% CI, 
0.83–4.59)/CGM OR (95% CI, 
0.37–2.05), TGM vs CGM OR 
1.02 (95% CI, 0.42–2.47)/CGF 
OR 2.27 (95% CI, 0.93–5.54)
Getahun et al20 2842 TGF, 2118 
TGM
Retrospective, electronic 
record-based cohort 
study
GHT unspecified in text Mean follow-up, 
TGF: 4 y; TGM: 
4.4 y
Myocardial infarction, TGF vs 
CGF HR 1.8 (95% CI, 1.1–2.9)*/
CGM HR 0.9 (95% CI, 0.6–1.5); 
TGM vs CGM HR 0.7 (95% CI, 
0.3–1.8)/CGF HR 1.3 (95% CI, 
0.5–3.9)
CGF indicates cisgender females; CGM, cisgender males; CPA, cyproterone acetate; GHT, gender-affirming hormone therapy; GNC, gender nonconforming; HR, 
hazard ratio; IHD, ischemic heart disease; IM, intramuscular; SIR, standardized incidence ratio; SMR, standardized mortality ratio; TGF, transgender females; and 
TGM, transgender males.
*Denotes statistical significance.
Table 2. Continued
Author, y Population Design GHT Exposure Study Duration Outcome Measure
flow-mediated and nitric oxide-induced vasodilation com-
pared with cisgender individuals. No improvements in exer-
cise-induced metabolic vasodilation were observed.32 Oral 
estrogen in 23 TGFs resulted in increased levels of IL (inter-
leukin)-6, IL-1, and IL-8 in the first few months of GHT and 
fell thereafter, while levels of the anti-oxidant enzyme super-
oxide dismutase were elevated throughout the 6-month study 
period, which was not apparent in those prescribed trans-
dermal estrogen.33 After 4 months of GHT endothelin levels 
increased in TGM and fell in TGF.34 Oral estrogen may also 
increase nitric oxide and decrease tissue plasminogen acti-
vator levels.35,36
Brachial-ankle pulse wave velocity was higher in GHT-
exposed versus untreated TGM with no difference in carotid 
augmentation index.22 GHT in TGMs results in higher bra-
chial artery diameter and reduced nitrate-induced vascular 
response, but similar endothelial function compared with that 
of age-matched controls.37 Reductions in estradiol in TGM 
treated with the aromatase inhibitor, anastrazole, in addition 
to parenteral testosterone esters, resulted in no change in 
flow-mediated dilation, however, a significant positive cor-
relation in common carotid compliance and distensibility 
coefficients were observed.38 In 56 transgender individuals, 
carotid intima-media thickness and flow-mediated dilation of 
the brachial artery was measured 2 to 3 months after gender 
reassignment procedures and compared with those receiving 
GHT alone.39 Those undergoing surgery experience a reduc-
tion in flow-mediated dilation and increased carotid intima-
media thickness.
Overall data describing the influence of GHT on vas-
cular structure and physiology is limited. The GETS (Gender 
Dysphoria Treatment in Sweden) study primarily aims to 
assess the physiological and epigenetic effects of initiat-
ing GHT on skeletal muscle and adipose tissue, and if such 
changes influence metabolism and body composition.40 
Secondary outcome measures include the assessment of ca-
rotid augmentation index, echocardiograms, coronary flow re-
serve, and carotid intima-media thickness.
Sex Steroids and the Vasculature
A compressive review of complexity of sex hormone receptor 
expression, signaling and regulation of vascular function is 
beyond the scope of this article. However, excellent reviews 
on this topic are available.41–44 In short, the vascular effects 
of estrogen are mediated via the estrogen receptors (ER-α, 
ER-β, and the GPER [G protein-coupled estrogen receptor]). 
These are expressed in endothelial, vascular smooth muscle, 
and myocardial cells (Figure 1). In mice, ER-α mediates pro-
tective effects of estrogen in response to vascular injury and 
atherosclerosis.45,46 In endothelial cells, ER-α has been shown 
to activate endothelium-dependent vasodilatation via endo-
thelial nitric oxide synthase, endothelial proliferation, and mi-
gration, and promotes carotid artery re-endothelialization.47,48 
Mouse models have also demonstrated an important role of 
ER-β in the regulation of vascular function and blood pressure 
49
 while loss of GPER action augments endothelium-depen-
dent vasoconstriction and promotes atheroma formation and 
inflammation.50
A paradoxical relationship, therefore, exists between the 
observed role of estrogen in the vasculature and the clinical 
outcomes observed in TGF. In postmenopausal CGF, estro-
gen’s age and exposure-dependent vasoprotective effects 
suggest a beneficial role in early, but not later stages, of 
atherogenesis.51–53 Similarly, in apolipoprotein E-deficient 
mice, exogenous estrogen precludes atheroma development 
but not the progression of established lesions.54 In addition 
to the greater atheroma burden associated with their natal 
sex, TGFs are deprived of the protection of endogenous life-
long estrogen exposure (Figure 2).55 Alterations to estrogen 
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receptor subtype expression, which is sex and tissue-specific, 
receptor sensitivity or signaling may contribute to increases 
in oxidative stress and inflammation in this relatively dys-
lipidemic, pro-hypertensive, and pro-thrombotic pheno-
type.33,56,57 Mechanistic studies exploring this relationship 
have yet to be performed.
Much like ERs, the AR (androgen receptor) is expressed 
in vascular endothelial and smooth muscle cells.44 In vitro 
studies demonstrate that testosterone acts as a vasodilator 
via both endothelium-dependent and independent mecha-
nisms.58,59 This action is mediated, in part, by inhibition 
of voltage-operated calcium channels and the activation 
of potassium channels on vascular smooth muscle cells.60 
Conversely, vasoconstrictive properties of testosterone 
have been observed in isolated and perfused rat coronary 
arteries.61 Testosterone has been shown to confer cardio-
protection after ischemia in isolated perfused hearts and 
ventricular myocytes from orchidectomized rats via upregu-
lation of the cardiac α1-adrenoceptor.62 In rats, testosterone 
also induces leukocyte migration via NADPH oxidase 
cyclooxygenase-dependent mechanisms and may contribute 
to inflammatory processes and oxidative stress in the vascu-
lature, thereby potentially increasing cardiovascular risk.63 
Testosterone induces apoptosis in vascular smooth muscle 
cells via the extrinsic apoptotic pathway with the involve-
ment of AR activation and mitochondria-generated reactive 
oxygen species.64
Consequently, testosterone has both vasoprotective and 
vasoinjurious actions. It is unclear why the latter does not 
precipitate cardiovascular risk in TGMs or if androgen dep-
rivation is responsible for an increased cardiovascular risk in 
TGF. This is further complicated by the use of gonadotropin-
releasing hormone agonists, which receptor is expressed in 
the cardiovascular system and may increase cardiovascular 
risk in the treatment of prostate cancer, albeit in the context 
of hypogonadism.65,66
Conclusions
Sexual dimorphism exists in cisgender people across all spec-
trums of diseases including immune response, inflammatory 
disorders, malignancy, clinical pharmacology, and psychi-
atry.67–71 Although this review focuses on vascular disease, 
GHT impacts other aspects of health such as bone metabolism 
and the risk of malignancy. Therefore a cross-disciplinary 
approach is required to provide transgender people with op-
timal care.9,10
Although, GHT is integral to the management of transgender 
individuals the majority of studies identified by this review 
are retrospective and do not offer insight into the mechanisms 
by which sex steroids may alter vascular physiology and sex 
hormone receptor status in transgender people.72,73 The dose, 
formulation and mode of hormone therapy are heterogeneous, 
and achievement and sustainment of target hormone levels 
are often omitted. Their interpretation is also confounded by 
rates of mental health disorders, substance abuse, and health 
inequalities in transgender populations, which will contribute 
to the burden of cardiovascular risk.74 Furthermore, the long-
term effects of pubertal suppression and subsequent introduc-
tion of GHT on vascular health in adolescents is unknown. 
Lastly, a consensus must be reached as to whether transgender 
individuals should be compared with their natal sex or their 
adopted gender.
Current evidence suggests that the use of estrogen by 
TGFs confers an increased risk of MI and ischemic stroke 
(Table 3). Whether this is a consequence of GHT or legacy 
effect of natal sex remains unclear as not all studies dem-
onstrate increased risk compared with CGMs. Conversely, 
TGMs lack any consistent or convincing evidence of 
increased risk of cardiovascular or cerebrovascular disease 
despite blood pressure elevations and dyslipidemia. The 
study of cardiovascular health and disease in transgender 
people is urgently required to implement better clinical care 
and evidence-based guidance.
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